TABLE 2.

Participant demographics for the PD-DBS speaker group.

ID	Sex	Age	MoCA	Years post-diagnosis	Years since DBS surgery	PD medications	LEED (mg)	Deviant perceptual characteristics
01	M	60	24	12	2	Levodopa, amantadine	300	Hoarse, breathy voice, monopitch, imprecise consonants, prolonged intervals
02	F	71	16	25	9	Levodopa	50	Hoarse, breathy voice, imprecise consonants, short rushes, fast rate
03	M	63	24	18	9	Amantadine, levodopa	430	Mild hypophonia, imprecise consonants, short rushes, high pitch
04	M	73	20	12	4	Levodopa	NA	Strained-strangled voice, imprecise consonants, prolonged phonemes, slow rate
05	M	56	27	16	6	Levodopa	NA	Harsh voice, imprecise consonants
06	M	59	16	13	5	Levodopa, amantadine, Sinemet	NA	Mild hypophonia, imprecise consonants, high pitch
07	F	69	25	16	3	Levodopa	550	Moderate hypophonia, strained-strangled voice, audible inspiration, voice breaks
08	M	66	28	14	6	Levodopa	NA	mild hypophonia, strained-strangled voice, pitch breaks, imprecise consonants
09	M	55	28	8	1	Levodopa	500	Imprecise consonants, hoarse voice, short rushes, fast rate
10	M	66	23	4	3	Levodopa	150	High pitch, hypernasality, imprecise consonants, short rushes
11	M	60	25	12	4	Levodopa, ropinirole	NA	Harsh, breathy voice, imprecise consonants, audible inspirations
12	M	66	28	14	7	Levodopa	500	Mild hypophonia, imprecise consonants, short rushes, fast rate
13	M	72	22	15	4	Levodopa	600	Imprecise consonants, breathy voice

PD, Parkinson’s disease; DBS, deep brain stimulation; MoCA, Montreal Cognitive Assessment; LEED, levodopa equivalent daily dose. Deviant perceptual characteristics for the PD groups correspond to features noted during the habitual monolog speech samples.